CA2324982A1 - Method for examining disease - Google Patents

Method for examining disease Download PDF

Info

Publication number
CA2324982A1
CA2324982A1 CA002324982A CA2324982A CA2324982A1 CA 2324982 A1 CA2324982 A1 CA 2324982A1 CA 002324982 A CA002324982 A CA 002324982A CA 2324982 A CA2324982 A CA 2324982A CA 2324982 A1 CA2324982 A1 CA 2324982A1
Authority
CA
Canada
Prior art keywords
opioid
disease
receptor
itching
dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002324982A
Other languages
English (en)
French (fr)
Inventor
Hiroo Kumagai
Takao Saruta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of CA2324982A1 publication Critical patent/CA2324982A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G01N2333/675—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin beta-Endorphins

Landscapes

  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002324982A 2000-05-08 2000-11-02 Method for examining disease Abandoned CA2324982A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000135043A JP4370683B2 (ja) 2000-05-08 2000-05-08 そう痒疾患の検査方法
JP135043/00 2000-05-08

Publications (1)

Publication Number Publication Date
CA2324982A1 true CA2324982A1 (en) 2001-11-08

Family

ID=18643206

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002324982A Abandoned CA2324982A1 (en) 2000-05-08 2000-11-02 Method for examining disease

Country Status (3)

Country Link
US (1) US6984493B1 (cg-RX-API-DMAC7.html)
JP (1) JP4370683B2 (cg-RX-API-DMAC7.html)
CA (1) CA2324982A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005011113D1 (de) * 2004-03-30 2009-01-02 Toray Industries Morphinanderivate als mittel gegen juckreiz
KR101334401B1 (ko) 2006-04-11 2013-11-29 한국생명공학연구원 아토피 피부 질환의 기전을 모니터링 할 수 있는 아토피피부 질환의 진단 또는 치료용 마커 단백질
KR101257307B1 (ko) 2006-05-22 2013-04-23 한국생명공학연구원 인간 혈청 프로테옴에서 발굴한 아토피 피부 질환의 기전을모니터링 할 수 있는 아토피 피부 질환의 진단 또는치료용 마커 단백질
WO2011049433A1 (en) * 2009-10-23 2011-04-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnosis and treatment of pruritis
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
KR20150003059A (ko) * 2013-06-28 2015-01-08 김종배 뇨 중 글리아돌핀(Gliadorphin) 농도 측정을 위한 면역분석법
CA3091752A1 (en) 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
CN118512451A (zh) 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine

Also Published As

Publication number Publication date
JP2001318095A (ja) 2001-11-16
JP4370683B2 (ja) 2009-11-25
US6984493B1 (en) 2006-01-10

Similar Documents

Publication Publication Date Title
Krief et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man.
US6984493B1 (en) Method for examining the involvement of opioid peptides in prurtis
Joseph et al. Plasma-tryptophan/neutral amino acid ratio and dexamethasone suppression in depression
SAKAI et al. Desmopressin Stimulation Test for Diagnosis of ACTH-Dependent Gushing's Syndrome
Marette et al. Regional variation in adipose tissue insulin action and GLUT4 glucose transporter expression in severely obese premenopausal women
Richer et al. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.
Bendtsen et al. Serotonin metabolism in chronic tension-type headache
Zhang et al. The visceral-fat-area-to-hip-circumference ratio as a predictor for insulin resistance in a Chinese population with type 2 diabetes
Siegmund et al. Effect of levothyroxine administration on intestinal P‐glycoprotein expression: Consequences for drug disposition
Pichon et al. Urinary and blood concentrations of β2-agonists in trained subjects: comparison between routes of use
Gianoulakis et al. Endorphins in individuals with high and low risk for development of alcoholism
HAMET et al. Effect of upright posture and isoproterenol infusion on cyclic adenosine monophosphate excretion in control subjects and patients with labile hypertension.
Acheson et al. Induction of cytochromes P-450 in pancreatic disease: consequence, coincidence or cause?
Merry et al. Hypothalamic-pituitary-adrenal function in chronic alcoholics
Remkova et al. Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension
WO2019137138A1 (zh) 人gpnmb蛋白或其拮抗剂或激动剂的用途
Rubenstein et al. Human spinal fluid methadone levels
D’Andrea et al. Platelet catecholamines in cluster headache
SHISHIBA et al. Discrepancy between thyroid-stimulating and thyrotropin-binding inhibitory activities of Graves' immunoglobulin Gs assessed in the mouse
Locong et al. Cortisol and catecholamines reponse to venisection by humans with different blood groups
US7947458B1 (en) Placental human neurokinin B precursor
Fitzpatrick et al. Circulating histamine and eosinophil cationic protein levels in nocturnal asthma
Fox et al. Cytokine mRNA expression in labial salivary glands and cytokine secretion in parotid saliva in Sjögren’s syndrome
AU606946B2 (en) Diagnosing obesity caused by a genetic abnormality and method of therapeutically treating genetically caused obesity
Huppertz et al. Comparative LCMS/MS drug analysis of paired urine, oral fluid and capillary blood samples in addiction therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued